Author:
Wijnhoven B. P. L.,Haustermans K.,Siersema P. D.
Reference14 articles.
1. AGA. Technical review on the management of Barrett’s esophagus. Gastroenterology 2011;140:e18–52.
2. Biere SS, Berge Henegouwen MI van, Maas KW, Bonavina L, Rosman C, Garcia JR, Gisbertz SS, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379(9829):1887–92.
3. Conroy T, Marchal F, Blazeby JM. Quality of life in patients with oesophageal and gastric cancer: an overview. Oncology 2006;70:391–402.
4. Gebski V, Burmeister B, Smithers BM, et al. Australasian gastro-intestinal trials group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–34.
5. Grünberger B, Raderer M, Schmidinger M, Hejna M. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Review. Anticancer Res. 2007;27(4C):2705–14.